# SVISCISVS

## **Customer Case Study**

Protein A Resin Reduction Achieved With Process Transfer From Batch to Resolute<sup>®</sup> BioSMB



## Customer Challenge

Sanofi's key driver for this study was to reduce the operating costs of existing purification steps with high resin costs. Regulatory concerns were to be tested by determining product quality consistency through process transfer and scale-up. The feasibility of extended purifications at production scale was also determined by evaluating Resolute<sup>®</sup> BioSMB system robustness.

#### **Customer Profile**

Company Name: Sanofi-Aventis

Company Location: Frankfurt am Main, Germany

Company Type: Large Biopharma

Industry: Health Care

Company Size: >100K Employees

Company Revenue: €36.126 Billion

Company Profile: www.sanofi.com/en/about-us



# Background Information

The aim of this study was to explore the benefits of multi-column chromatography and application to a perfusion based process. Resin savings and the capability of continuous chromatography to run for long process times were important decision factors in the selection of the technology.

This case study centred on transferring an existing batch chromatography process into a multi column format and then scaling up that process to an continuous perfusion run. The bioreactor was a 50 L single-use perfusion setup where the maintenance of aseptic conditions and flow path robustness were key to meet the target of a 10 day run time that ultimately processed a feedstock volume of approximately 800 L.

# Provided Solution

Sanofi used the Resolute<sup>®</sup> BioSMB PD system to conduct a bench-scale proof of concept for continuous chromatography. Four pre-packed columns with Protein A resin, each with a volume of 5.7 mL (1.2 cm ID × 5 cm BH), were used for this set of experiments. They tested three process settings to determine if the continuous mode of operation was robust.

Scale up to the pilot scale was conducted with a Resolute<sup>®</sup> BioSMB 80 system. Four Protein A columns, each with a volume of ~200 mL (5 cm ID × 10 cm BH), were used, and the same process settings were used to determine if scale-up had any effect on product quality or any other operating results.

The Resolute<sup>®</sup> BioSMB 80 was also used on an extended 10-day run to test the system's robustness and the aseptic claims of the single-use manifold. Three of the 200 mL Protein A columns were used, leading to a process flowrate of 5 L/h.

### **Project Key Indicators**

Molecule type: mAbs, Biosimilars


Process Steps: Downstream Chromatography

Process Scale: Resolute<sup>®</sup> BioSMB PD: PD | Bench Scale

Resolute® BioSMB 80: Production Scale (Commercial and Clinical)

Used Products | Solutions | Services: • Resolute<sup>®</sup> BioSMB PD

Resolute<sup>®</sup> BioSMB 80



# Outcome

By transferring their existing Protein A step to the Resolute® BioSMB platform, Sanofi saw consistent process performance and product quality compared to batch mode and benefited from a 400 – 500% increase in productivity and greater than 80% reduction Protein-A resin requirement. The standard process architecture between the Resolute® BioSMB PD and Resolute® BioSMB 80 enabled seamless scalability from bench to production-scale. The perfusion optimized single-use manifold of the Resolute® BioSMB 80 system allowed for a robust, 10-day continuous purification process indicating that the functionally closed, single-use, gamma-irradiated flow path is robust in design and suitable for single-use manufacturing facilities. Sanofi also demonstrated that Resolute® BioSMB technology could be optimized for commercial (maximizing load capacity) or clinical processing (minimize resin requirement).



## At a Glance

# 400-500% increase in productivity

80% reduction Protein-A resin requirement

## Seamless scalability from bench to production-scale

# No measurable bioburden

or contamination was observed during the 10-day straight run



## Before: Batch

- Load capacity: 30 g/L @ 4 min contact time
- 14 g/L/hr specific productivity
- 100 L Protein A resin



## After: Resolute<sup>®</sup> BioSMB Clinical

- Load capacity: 32 g/L @ 1 min contact time, higher capacity at faster flowrates
- 65 g/L/hr specific productivity, significantly more productive
- 11 L Protein A resin, 89% reduction in resin usage

#### Germany

### USA

Sartorius Stedim Biotech GmbH August-Spindler-Strasse 11 37079 Goettingen Phone +49 551 308 0

### For More Information, Visit

www.sartorius.com

Sartorius Stedim North America Inc. 565 Johnson Avenue Bohemia, NY 11716 Toll-Free +1 800 368 7178

Specifications subject to change without notice.

<sup>© 2022</sup> Sartorius Stedim Biotech GmbH, August-Spindler-Strasse 11, 37079 Goettingen, Germany